

6 Literaturverzeichnis

1. Rojas, M., Yao, S. und Lin, Y.Z. (1996) Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. *J Biol Chem*, **271**, 27456-61.
2. Derossi, D., Chassaing, G. und Prochiantz, A. (1998) Trojan peptides: the penetratin system for intracellular delivery. *Trends Cell Biol*, **8**, 84-7.
3. Oess, S. und Hildt, E. (2000) Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. *Gene Ther*, **7**, 750-8.
4. Hall, W.A. (1997) Target toxin therapy. In Kornblith, P.L.a.W., M.D. (ed.), *Advances in Neuro-Oncology II*. Futura, NY, pp. 505-516.
5. Nagy, J.M., Jesmin, J., Servos, S., Cass, A.E., et al. (1998) Site-directed mutants of the catalase-peroxidase from *Mycobacterium tuberculosis*. *Biochem Soc Trans*, **26**, S281.
6. Folkman, W., Kusmierk, J.T. und Singer, B. (1990) A new one-step method for the preparation of 3',5'-bisphosphates of acid-labile deoxynucleosides. *Chem Res Toxicol*, **3**, 536-9.
7. Polverini, P.J. und Leibovich, S.J. (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. *Lab Invest*, **51**, 635-42.
8. Bicknell, R. und Harris, A.L. (1991) Novel growth regulatory factors and tumour angiogenesis. *Eur J Cancer*, **27**, 781-5.
9. Juliano, R.L. und Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta*, **455**, 152-62.
10. Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science*, **258**, 1650-4.
11. Scheffer, G.L., Wijngaard, P.L., Flens, M.J., Izquierdo, M.A., et al. (1995) The drug resistance-related protein LRP is the human major vault protein. *Nat Med*, **1**, 578-82.
12. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Giaccone, G., et al. (1996) Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. *Am J Pathol*, **148**, 877-87.
13. Wang, C.T., Tsai, W.J., Chang, S.M., Shiao, Y.J., et al. (1987) Different susceptibilities of platelet phospholipids to various phospholipases and modifications induced by thrombin. Possible evidence of rearrangement of lipid domains. *Biochim Biophys Acta*, **899**, 205-12.
14. Bosslet, K., Straub, R., Blumrich, M., Czech, J., et al. (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. *Cancer Res*, **58**, 1195-201.
15. Leenders, R.G., Damen, E.W., Bijsterveld, E.J., Scheeren, H.W., et al. (1999) Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. *Bioorg Med Chem*, **7**, 1597-610.
16. Pentheroudakis, G. und Twelves, C. (2002) Capecitabine (Xeloda): from the laboratory to the patient's home. *Clin Colorectal Cancer*, **2**, 16-23.
17. Lasic, D.D. und Papahadjopoulos, D. (1995) Liposomes revisited. *Science*, **267**, 1275-6.
18. Hubert, A., Lyass, O., Pode, D. und Gabizon, A. (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. *Anticancer Drugs*, **11**, 123-7.

19. Toma, S., Tucci, A., Villani, G., Carteni, G., et al. (2000) Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). *Anticancer Res*, **20**, 485-91.
20. Koukourakis, M.I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S.C., et al. (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. *J Clin Oncol*, **17**, 3512-21.
21. Vallera, D.A., Jin, N., Baldrice, J.M., Panoskaltis-Mortari, A., et al. (2000) Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. *Cancer Res*, **60**, 976-84.
22. Ehrlich, P. (1900) On immunity with special reference to cell life. *Proc R Soc*, **66**, 424-448.
23. Edelman, G.M., Gall, W.E., Waxdal, M.J. & Konigsberg, W.H. (1968) The covalent structure of a human gamma G-immunoglobulin. I. Isolation and characterization of the whole molecule, the polypeptide chains, and the tryptic fragments. *Biochemistry*, **7**, 1950-1958.
24. Kohler, G. und Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*, **256**, 495-497.
25. Mellstedt, H., Frodin, J.E. und Masucci, G. (1989) Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma. *Oncology (Huntingt)*, **3**, 25-32; discussion 37-9, 42.
26. Mezzanzanica, D., Canevari, S. und Colnaghi, M.I. (1991) Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. *Int J Clin Lab Res*, **21**, 159-64.
27. Bolhuis, R.L., Lamers, C.H., Goey, S.H., Eggermont, A.M., et al. (1992) Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. *Int J Cancer Suppl*, **7**, 78-81.
28. Debatin, K.M. und Krammer, P.H. (1995) Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. *Leukemia*, **9**, 815-20.
29. Trauth, B.C., Klas, C., Peters, A.M., Matzku, S., et al. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science*, **245**, 301-5.
30. Baselga, J. und Mendelsohn, J. (1994) Receptor blockade with monoclonal antibodies as anti-cancer therapy. *Pharmacol Ther*, **64**, 127-54.
31. Schneider-Gadicke, E. und Riethmuller, G. (1995) Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours. *Eur J Cancer*, **31A**, 1326-30.
32. Hainsworth, J.D., Burris, H.A., 3rd, Morrissey, L.H., Litchy, S., et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. *Blood*, **95**, 3052-6.
33. Zompi, S., Tulliez, M., Conti, F., Leblond, V., et al. (2000) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. *J Hepatol*, **32**, 521-7.
34. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., et al. (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. *Semin Oncol*, **26**, 78-83.
35. Kosterink, J.G.W., Helfrich, W. und Leij, L.F.M.H. (2001) Strategies for Specific Drug targeting to Tumour Cells. In Molema, G., Meijer, D.K.F (ed.), *Drug Targeting*. Wiley-VCH, Weinheim, vol. 12, pp. 223.
36. Staerz, U.D., Kanagawa, O. und Bevan, M.J. (1985) Hybrid antibodies can target sites for attack by T cells. *Nature*, **314**, 628-31.
37. Repp, R., Valerius, T. & Bargou, R. (2001) Bispecific antibodies in hematology and oncology. *Internist (Berl)*, **42**, 854-859.
38. Dillman, R.O., Johnson, D.E., Ogden, J. und Beidler, D. (1989) Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. *Mol Biother*, **1**, 250-5.

39. Ghose, T., Norvell, S.T., Guclu, A., Cameron, D., et al. (1972) Immunochemotherapy of cancer with chlorambucil-carrying antibody. *Br Med J*, **3**, 495-9.
40. King, H.D., Yurgaitis, D., Willner, D., Firestone, R.A., et al. (1999) Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. *Bioconjug Chem*, **10**, 279-88.
41. Shen, W.C. und Ryser, H.J. (1981) cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. *Biochem Biophys Res Commun*, **102**, 1048-54.
42. Franssen, E.J., Koiter, J., Kuipers, C.A., Bruins, A.P., et al. (1992) Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. *J Med Chem*, **35**, 1246-59.
43. Mueller, B.M., Wrasidlo, W.A. und Reisfeld, R.A. (1990) Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. *Bioconjug Chem*, **1**, 325-30.
44. Midoux, P., Negre, E., Roche, A.C., Mayer, R., et al. (1990) Drug targeting: anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosphonylmethoxyethyl)adenine. *Biochem Biophys Res Commun*, **167**, 1044-9.
45. Kok, R.J., Grijpstra, F., Walthuis, R.B., Moolenaar, F., et al. (1999) Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. *J Pharmacol Exp Ther*, **288**, 281-5.
46. Plourde, R., Phillips, A.T., Wu, C.H., Hays, R.M., et al. (1996) A hepatocyte-targeted conjugate capable of delivering biologically active colchicine in vitro. *Bioconjug Chem*, **7**, 131-7.
47. Shen, W.C., Ryser, H.J. und LaManna, L. (1985) Disulfide spacer between methotrexate and poly(D-lysine). A probe for exploring the reductive process in endocytosis. *J Biol Chem*, **260**, 10905-8.
48. Umemoto, N., Kato, Y. und Hara, T. (1989) Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody. *Cancer Immunol Immunother*, **28**, 9-16.
49. Arunachalam, B., Phan, U.T., Geuze, H.J. und Cresswell, P. (2000) Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). *Proc Natl Acad Sci U S A*, **97**, 745-50.
50. Thorpe, P.E., Wallace, P.M., Knowles, P.P., Relf, M.G., et al. (1987) New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. *Cancer Res*, **47**, 5924-31.
51. Arpicco, S., Dosio, F., Brusa, P., Crosasso, P., et al. (1997) New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability. *Bioconjug Chem*, **8**, 327-37.
52. Seymour, L.W., Soye, H., De Marre, A., Shoaibi, M.A., et al. (1996) Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation. *Anticancer Drug Des*, **11**, 351-65.
53. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. *Clin Cancer Res*, **7**, 1490-6.
54. Kreitman, R.J. und Pastan, I. (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. *Cancer Res*, **58**, 968-75.
55. Pincus, S.H. (1996) Therapeutic potential of anti-HIV immunotoxins. *Antiviral Res*, **33**, 1-9.
56. Wu, M. (1997) Are immunoconjugates useful for therapy with autoimmune diseases? *Int J Immunopharmacol*, **19**, 83-93.
57. Endo, Y., Chan, Y.L., Lin, A., Tsurugi, K., et al. (1988) The cytotoxins alpha-sarcin and ricin retain their specificity when tested on a synthetic oligoribonucleotide (35-mer) that mimics a region of 28 S ribosomal ribonucleic acid. *J Biol Chem*, **263**, 7917-20.

58. Propper, D.J., Saunders, M.P., Salisbury, A.J., Long, L., et al. (1999) Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. *Clin Cancer Res*, **5**, 1682-9.
59. Heimer, R. und Sartorelli, A.C. (1992) RNA-directed actions of 5-fluorouridine in hemin stimulated K-562 erythroleukemia cells. *Cancer Biochem Biophys*, **12**, 221-39.
60. Wilkinson, D.S., Tlsty, T.D. und Hanas, R.J. (1975) The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. *Cancer Res*, **35**, 3014-20.
61. Bonfanti, M., Taverna, S., Salmons, M., D'Incalci, M., et al. (1997) p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. *Cancer Res*, **57**, 1442-6.
62. Van Ness, B.G., Howard, J.B. und Bodley, J.W. (1980) ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. *J Biol Chem*, **255**, 10717-20.
63. Van Ness, B.G., Howard, J.B. und Bodley, J.W. (1980) ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. *J Biol Chem*, **255**, 10710-6.
64. Chung, D.W. und Collier, R.J. (1977) The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin. *Biochim Biophys Acta*, **483**, 248-57.
65. Pavlovskis, O.R., Iglewski, B.H. und Pollack, M. (1978) Mechanism of action of *Pseudomonas aeruginosa* exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. *Infect Immun*, **19**, 29-33.
66. Hausner, T.P., Atmadja, J. und Nierhaus, K.H. (1987) Evidence that the G2661 region of 23S rRNA is located at the ribosomal binding sites of both elongation factors. *Biochimie*, **69**, 911-23.
67. Siegall, C.B. (1994) Targeted toxins as anticancer agents. *Cancer*, **74**, 1006-12.
68. Endo, Y. und Tsurugi, K. (1987) RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. *J Biol Chem*, **262**, 8128-30.
69. Stirpe, F., Bailey, S., Miller, S.P. und Bodley, J.W. (1988) Modification of ribosomal RNA by ribosome-inactivating proteins from plants. *Nucleic Acids Res*, **16**, 1349-57.
70. Tondini, C., Pap, S.A., Hayes, D.F., Elias, A.D., et al. (1990) Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. *Cancer Res*, **50**, 1170-5.
71. Hall, W.A. und Fodstad, O. (1992) Immunotoxins and central nervous system neoplasia. *J Neurosurg*, **76**, 1-12.
72. Murphy, J.R., Olsnes, S., Melton-Celsa, A.R., et al. (1997) *Guidebook to Protein Toxins and Their Use in Cell Biology*. Oxford University Press, New York.
73. O'Hare, M., Roberts, L.M., Thorpe, P.E., Watson, G.J., et al. (1987) Expression of ricin A chain in *Escherichia coli*. *FEBS Lett*, **216**, 73-8.
74. Barthelemy, I., Martineau, D., Ong, M., Matsunami, R., et al. (1993) The expression of saporin, a ribosome-inactivating protein from the plant *Saponaria officinalis*, in *Escherichia coli*. *J Biol Chem*, **268**, 6541-8.
75. Legname, G., Gromo, G., Lord, J.M., Monzini, N., et al. (1993) Expression and activity of pre-dianthin 30 and dianthin 30. *Biochem Biophys Res Commun*, **192**, 1230-7.
76. Nolan, P.A., Garrison, D.A. und Better, M. (1993) Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from *Gelonium multiflorum*. *Gene*, **134**, 223-7.
77. Iglewski, B.H. und Kabat, D. (1975) NAD-dependent inhibition of protein synthesis by *Pseudomonas aeruginosa* toxin. *Proc Natl Acad Sci U S A*, **72**, 2284-2288.
78. Olsnes, S., Fernandez-Puentes, C., Carrasco, L. und Vazquez, D. (1975) Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains. *Eur J Biochem*, **60**, 281-8.

79. May, M.J., Hartley, M.R., Roberts, L.M., Krieg, P.A., et al. (1989) Ribosome inactivation by ricin A chain: a sensitive method to assess the activity of wild-type and mutant polypeptides. *Embo J*, **8**, 301-8.
80. Brigotti, M., Barbieri, L., Valbonesi, P., Stirpe, F., et al. (1998) A rapid and sensitive method to measure the enzymatic activity of ribosome-inactivating proteins. *Nucleic Acids Res*, **26**, 4306-7.
81. VanDusen, W.J., Fu, J., Bailey, F.J., Burke, C.J., et al. (1997) Adenine quantitation in yeast extracts and fermentation media and its relationship to protein expression and cell growth in adenine auxotrophs of *Saccharomyces cerevisiae*. *Biotechnol Prog*, **13**, 1-7.
82. Zamboni, M., Brigotti, M., Rambelli, F., Montanaro, L., et al. (1989) High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. *Biochem J*, **259**, 639-43.
83. Fujimori, H., Sasaki, T., Hibi, K., Senda, M., et al. (1990) Measurement of adenine nucleotide levels with an adenine analyser as an index of freshness of porgy. *J Chromatogr*, **528**, 305-14.
84. Frankel, A.E., Tagge, E.P. und Willingham, M.C. (1995) Clinical trials of targeted toxins. *Semin Cancer Biol*, **6**, 307-17.
85. Vitetta, E.S., Fulton, R.J., May, R.D., Till, M., et al. (1987) Redesigning nature's poisons to create anti-tumor reagents. *Science*, **238**, 1098-104.
86. LoBuglio, A.F. und Saleh, M.N. (1992) Advances in monoclonal antibody therapy of cancer. *Am J Med Sci*, **304**, 214-24.
87. Reiter, Y., Brinkmann, U., Lee, B. und Pastan, I. (1996) Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. *Nat Biotechnol*, **14**, 1239-45.
88. Reiter, Y. (2001) Recombinant immunotoxins in targeted cancer cell therapy. *Adv Cancer Res*, **81**, 93-124.
89. Yarden, Y. und Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*, **2**, 127-37.
90. Lenferink, A.E., Pinkas-Kramarski, R., van de Poll, M.L., van Vugt, M.J., et al. (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. *Embo J*, **17**, 3385-97.
91. Salomon, D.S., Brandt, R., Ciardiello, F. und Normanno, N. (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol*, **19**, 183-232.
92. De Miguel, P., Royuela, Bethencourt, R., Ruiz, A., et al. (1999) Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. *Cytokine*, **11**, 722-7.
93. Normanno, N., Kim, N., Wen, D., Smith, K., et al. (1995) Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. *Breast Cancer Res Treat*, **35**, 293-7.
94. Pedersen, M.W., Meltorn, M., Damstrup, L. und Poulsen, H.S. (2001) The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. *Ann Oncol*, **12**, 745-60.
95. Woodburn, J.R. (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol Ther*, **82**, 241-50.
96. O'Dwyer P, J. und Benson, A.B., 3rd (2002) Epidermal growth factor receptor-targeted therapy in colorectal cancer. *Semin Oncol*, **29**, 10-7.
97. Olsen, E., Duvic, M., Frankel, A., Kim, Y., et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *J Clin Oncol*, **19**, 376-88.
98. Laske, D.W., Youle, R.J. und Oldfield, E.H. (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. *Nat Med*, **3**, 1362-8.

99. Engebraaten, O., Hjortland, G.O., Juell, S., Hirschberg, H., et al. (2002) Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. *Int J Cancer*, **97**, 846-52.
100. Kreitman, R.J. (2001) Toxin-labeled monoclonal antibodies. *Curr Pharm Biotechnol*, **2**, 313-25.
101. Decker, T., Hipp, S., Kreitman, R.J., Pastan, I., et al. (2002) Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. *Blood*, **99**, 1320-6.
102. Grossbard, M.L., Multani, P.S., Freedman, A.S., O'Day, S., et al. (1999) A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. *Clin Cancer Res*, **5**, 2392-8.
103. Schnell, R., Staak, O., Borchmann, P., Schwartz, C., et al. (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. *Clin Cancer Res*, **8**, 1779-86.
104. Schnell, R., Vitetta, E., Schindler, J., Barth, S., et al. (1998) Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. *Leuk Lymphoma*, **30**, 525-37.
105. Multani, P.S., O'Day, S., Nadler, L.M. und Grossbard, M.L. (1998) Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. *Clin Cancer Res*, **4**, 2599-604.
106. Frankel, A.E., Kreitman, R.J. und Sausville, E.A. (2000) Targeted toxins. *Clin Cancer Res*, **6**, 326-34.
107. Kreitman, R.J. (2001) Toxin-labeled monoclonal antibodies. *Curr Pharm Biotechnol*, **2**, 313-25.
108. Jain, R.K. (1996) Delivery of molecular medicine to solid tumors. *Science*, **271**, 1079-80.
109. Jain, R.K. (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. *Cancer Metastasis Rev*, **9**, 253-66.
110. Au, J.L.-S., Jang, S.H., Zheng, J., Chen, C.-T., et al. (2001) Determinants of drug delivery and transport to solid tumors. *J Control Release*, **74**, 31-46.
111. Brinkmann, U. und Pastan, I. (1994) Immunotoxins against cancer. *Biochim Biophys Acta*, **1198**, 27-45.
112. Keppler-Hafkemeyer, A., Kreitman, R.J. und Pastan, I. (2000) Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. *Int J Cancer*, **87**, 86-94.
113. FitzGerald, D.J., Willingham, M.C., Cardarelli, C.O., Hamada, H., et al. (1987) A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. *Proc Natl Acad Sci U S A*, **84**, 4288-92.
114. Mickisch, G.H., Pai, L.H., Siegmund, M., Campain, J., et al. (1993) Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. *J Urol*, **149**, 174-8.
115. Frankel, A.E., Hall, P.D., McLain, C., Safa, A.R., et al. (1998) Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. *Bioconjug Chem*, **9**, 490-6.
116. Perentesis, J.P., Waddick, K.G., Bendel, A.E., Shao, Y., et al. (1997) Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. *Clin Cancer Res*, **3**, 347-55.
117. Chiron, M.F., Fryling, C.M. und FitzGerald, D.J. (1994) Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. *J Biol Chem*, **269**, 18167-76.
118. O'Hare, M., Brown, A.N., Hussain, K., Gebhardt, A., et al. (1990) Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. *Febs Lett*, **273**, 200-4.

119. Goyal, A. und Batra, J.K. (2000) Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. *Biochem J*, **345 Pt 2**, 247-54.
120. Conner, G.E. (1998) Cathepsin D. In Woessner, J.F. (ed.), *Handbook of Proteolytic Enzymes*. Academic Press, London and San Diego, pp. 828-36.
121. Rejmanova, P., Kopecek, J., Duncan, R. und Lloyd, J.B. (1985) Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. *Biomaterials*, **6**, 45-8.
122. Vasey, P.A., Kaye, S.B., Morrison, R., Twelves, C., et al. (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. *Clin Cancer Res*, **5**, 83-94.
123. Fitzpatrick, J.J. und Garnett, M.C. (1995) Studies on the mechanism of action of an MTX-HSA-MoAb conjugate. *Anticancer Drug Des*, **10**, 11-24.
124. Wolf, B.B. und Green, D.R. (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. *J Biol Chem*, **274**, 20049-52.
125. Thornberry, N.A. und Lazebnik, Y. (1998) Caspases: enemies within. *Science*, **281**, 1312-6.
126. Ehlert, J.E. und Kubbutat, M.H. (2001) Apoptosis and its relevance in cancer therapy. *Onkologie*, **24**, 433-40.
127. Gansauge, S., Gansauge, F., Yang, Y., Muller, J., et al. (1998) Interleukin-1 beta converting enzyme (caspase-1) is overexpressed in the adenocarcinoma of the pancreas. *Cancer Res*, **58**, 2703-06.
128. Krajewski, S., Gascoyne, R., Zapata, J., Krajewska, M., et al. (1997) Immunolocalization of ICE/Ced-3-family protease, Cpp32 (Caspase-3) in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. *Blood*, **89**, 3817-25.
129. Morimoto, H. und Bonavida, B. (1992) Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. *J Immunol*, **149**, 2089-94.
130. Kochi, S.K. und Collier, R.J. (1993) DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. *Exp Cell Res*, **208**, 296-302.
131. Keppler-Hafkemeyer, A., Brinkmann, U. und Pastan, I. (1998) Role of caspases in immunotoxin-induced apoptosis of cancer cells. *Biochemistry*, **37**, 16934-42.
132. Houchins, J.P. (2000) Immunotoxin-induced apoptosis. *Stem Cells*, **18**, 384-5.
133. Thornton, K., Wang, Y., Weiner, H. und Gorenstein, D.G. (1993) Import, processing, and two-dimensional NMR structure of a linker-deleted signal peptide of rat liver mitochondrial aldehyde dehydrogenase. *J Biol Chem*, **268**, 19906-14.
134. Zhou, J., Bai, Y. und Weiner, H. (1995) Proteolysis prevents in vivo chimeric fusion protein import into yeast mitochondria. Cytosolic cleavage and subcellular distribution. *J Biol Chem*, **270**, 16689-93.
135. Moore, S.E. und Spiro, R.G. (1994) Intracellular compartmentalization and degradation of free polymannose oligosaccharides released during glycoprotein biosynthesis. *J Biol Chem*, **269**, 12715-21.
136. Wiertz, E.J., Tortorella, D., Bogyo, M., Yu, J., et al. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature*, **384**, 432-8.
137. Lindgren, M., Hallbrink, M., Prochiantz, A. und Langel, U. (2000) Cell-penetrating peptides. *Trends Pharmacol Sci*, **21**, 99-103.
138. Schwarze, S.R. und Dowdy, S.F. (2000) In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. *Trends Pharmacol Sci*, **21**, 45-8.

139. Rojas, M., Donahue, J.P., Tan, Z. und Lin, Y.Z. (1998) Genetic engineering of proteins with cell membrane permeability. *Nat Biotechnol*, **16**, 370-5.
140. Caron, N.J., Torrente, Y., Camirand, G., Bujold, M., et al. (2001) Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. *Mol Ther*, **3**, 310-8.
141. Elliott, G. und O'Hare, P. (1997) Intercellular trafficking and protein delivery by a herpesvirus structural protein. *Cell*, **88**, 223-33.
142. Rojas, M., Yao, S. und Lin, Y.Z. (1996) Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. *J Biol Chem*, **271**, 27456-27461.
143. Oess, S. und Hildt, E. (2000) Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. *Gene Ther*, **7**, 750-758.
144. Vives, E., Brodin, P. und Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J Biol Chem*, **272**, 16010-7.
145. Hanahan, D. (1983) Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol*, **166**, 557-580.
146. Lottspeich, F. und Zorbras, H. (1998) *Bioanalytik*. Spektrum Akademischer Verlag, Heidelberg Berlin.
147. Sanger, F., Nicklen, S. & Coulson, A.R (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A*, **74**, 5463-5467.
148. Matasova, N.B., Myltseva, S. V., Zenkova, M. A., Graifer, D. M., und Vladimirov, S.N., and Karpova, G. G. (1991) Isolation of ribosomal subunits containing intact rRNA from human placenta: Estimation of functional activity of 80S ribosomes. *Anal. Biochem*, **198**, 219-223.
149. Yu, W., Sanchez, H. und Schuster, W. (1998) Assays for investigating RNA editing in plant mitochondria. *Methods*, **15**, 63-74.
150. Fabbrini, M.S., Rappocciolo, E., Carpani, D., Solinas, M., et al. (1997) Characterization of a saporin isoform with lower ribosome-inhibiting activity. *Biochem J*, **322 (Pt 3)**, 719-27.
151. Laemmli, U.K. und . (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, **227**, 680-685.
152. Larsson, R. und Nygren, P. (1989) A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. *Anticancer Res*, **9**, 1111-9.
153. Dignam, J.D., Martin, P.L., Shastry, B.S. und Roeder, R.G. (1983) Eukaryotic gene transcription with purified components. *Methods Enzymol*, **101**, 582-98.
154. Barbieri, L., Valbonesi, P., Bonora, E., Gorini, P., et al. (1997) Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A). *Nucleic Acids Res*, **25**, 518-22.
155. Kawooya, J.K., Treat, J.C., Kirschner, R.J., Sears, M.W., et al. (1995) The expression, affinity purification and characterization of recombinant *Pseudomonas* exotoxin 40 (PE40) secreted from *Escherichia coli*. *J Biotechnol*, **42**, 9-22.
156. Li, B.Y., Frankel, A.E. und Ramakrishnan, S. (1992) High-level expression and simplified purification of recombinant ricin A chain. *Protein Expr Purif*, **3**, 386-94.
157. vanderSpek, J.C. und Murphy, J.R. (2000) Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells. *Methods Enzymol*, **327**, 239-49.
158. Tang, W., Sun, Z.Y., Pannell, R., Gurewich, V., et al. (1997) An efficient system for production of recombinant urokinase-type plasminogen activator. *Protein Expr Purif*, **11**, 279-83.
159. Morris, K.N. und Wool, I.G. (1994) Analysis of the contribution of an amphiphilic alpha-helix to the structure and to the function of ricin A chain. *Proc Natl Acad Sci U S A*, **91**, 7530-3.
160. Munishkin, A. und Wool, I.G. (1995) Systematic deletion analysis of ricin A-chain function. Single amino acid deletions. *J Biol Chem*, **270**, 30581-7.

161. Fordham-Skelton, A.P., Taylor, P.N., Hartley, M.R. und Croy, R.R. (1991) Characterisation of saporin genes: in vitro expression and ribosome inactivation. *Mol Gen Genet*, **229**, 460-6.
162. Ricci, C., Polito, L., Nanni, P., Landuzzi, L., et al. (2002) HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. *J Immunother*, **25**, 314-23.
163. Molloy, S.S., Anderson, E.D., Jean, F. und Thomas, G. (1999) Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. *Trends Cell Biol*, **9**, 28-35.
164. Denault, J.B. und Leduc, R. (1996) Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. *FEBS Lett*, **379**, 113-6.
165. Gordon, V.M., Klimpel, K.R., Arora, N., Henderson, M.A., et al. (1995) Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. *Infect Immun*, **63**, 82-7.
166. Tsuneoka, M., Nakayama, K., Hatsuzawa, K., Komada, M., et al. (1993) Evidence for involvement of furin in cleavage and activation of diphtheria toxin. *J Biol Chem*, **268**, 26461-5.
167. Keller, J. (2002) Entwicklung molekularer Adapter zur Optimierung von Immunotoxinen. *Inaugural Dissertation*. Freie Universität Berlin, Berlin.
168. Fitzpatrick, J.J. und Garnett, M.C. (1995) Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers. *Anticancer Drug Des*, **10**, 1-9.
169. Keller, J., Heisler, I., Tauber, R. und Fuchs, H. (2001) Development of a novel molecular adapter for the optimization of immunotoxins. *J Control Release*, **74**, 259-61.
170. Chandler, L.A., Sosnowski, B.A., McDonald, J.R., Price, J.E., et al. (1998) Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. *Int J Cancer*, **78**, 106-11.
171. Ballard, F.J. (1985) Regulation of protein breakdown by epidermal growth factor in A431 cells. *Exp Cell Res*, **157**, 172-80.
172. Pandiella, A., Magni, M., Lovisolo, D. und Meldolesi, J. (1989) The effect of epidermal growth factor on membrane potential. Rapid hyperpolarization followed by persistent fluctuations. *J Biol Chem*, **264**, 12914-21.
173. Azemar, M., Schmidt, M., Arlt, F., Kennel, P., et al. (2000) Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. *Int J Cancer*, **86**, 269-75.
174. Larsson, R., Nygren, P., Ekberg, M. und Slater, L. (1990) Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. *Leukemia*, **4**, 567-71.
175. Csoka, K., Larsson, R., Tholander, B., Gerdin, E., et al. (1994) Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). *Gynecol Oncol*, **54**, 163-70.
176. Riordan, H.D., Riordan, N.H., Meng, X., Zhong, J., et al. (1994) Improved microplate fluorometer counting of viable tumor and normal cells. *Anticancer Res*, **14**, 927-31.
177. Cavallaro, U., Nykjaer, A., Nielsen, M. und Soria, M.R. (1995) Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. *Eur J Biochem*, **232**, 165-71.
178. Lorenzetti, I., Meneguzzi, A., Fracasso, G., Potrich, C., et al. (2000) Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. *Int J Cancer*, **86**, 582-9.
179. Molloy, S.S., Bresnahan, P.A., Leppla, S.H., Klimpel, K.R., et al. (1992) Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. *J Biol Chem*, **267**, 16396-402.
180. Klimpel, K.R., Molloy, S.S., Thomas, G. und Leppla, S.H. (1992) Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. *Proc Natl Acad Sci U S A*, **89**, 10277-81.

181. Vieira, A.V., Lamaze, C. und Schmid, S.L. (1996) Control of EGF receptor signaling by clathrin-mediated endocytosis. *Science*, **274**, 2086-9.
182. Bachran, C. (2002) Optimierung und funktionelle Charakterisierung neuartiger Immunoadaptortoxine mit verschiedenen tumorspezifischen Liganden. *Diplomarbeit*. Freie Universität Berlin, Berlin.
183. Garnett, M.C. (2001) Targeted drug conjugates: principles and progress. *Adv Drug Deliv Rev*, **53**, 171-216.
184. Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., et al. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. *N Engl J Med*, **345**, 241-7.
185. Bennett, M.J., Lebron, J.A. und Bjorkman, P.J. (2000) Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. *Nature*, **403**, 46-53.